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Biotechnology Overview: 1987
JEFFREY L. FOX

jeffrey L. Fox is a freelance science writer in Washington D. C., currently affiliated with Rio/Technology and ASM News.

"'Biotechnology' is a terrible term," says David Kingsbury of
the National Science Foundation, who has been chairing the
federal-wide effort to coordinate biotechnology regulations
and guidelines (1). Although definitions of biotechnology
have changed often during recent years, the word's meaning
has seldom proved a serious stumbling block However, in
1986, federal officials renewed the debate over how best to
define the term because of a troublesome dilemma they find
themselves facing. Indeed, even their reluctance to close this
long-lived debate suggests a useful purpose is being served by
keeping the definition of biotechnology from becoming too
precise.
The dilemma over biotechnology arises because of the dual
missions of research and regulation for which so many federal
agencies are responsible. As interest in biotechnology grew
rapidly during the past 5 to 10 years, members of Congress
have pressed agency officials to show they were giving proper
support to this emerging enterprise. Although its growth in
the private sector has been fast and enormous, no one questions the impetus stemmed from federally sponsored
research-originally, largely from basic biomedical research
underwritten by the National Institutes of Health (NIH). Other
agencies have been urged to join in supporting biotechnology
and, wherever possible, to induce researchers whom they
fund to modernize their own efforts by adopting its powerful
tools.
Following that path has not proved a straightforward
assignment, however. Because many of the same federal
agencies also share a responsibility for regulating biotechnology research and its products, agency officials often find
themselves faced with two very different agendas on the same
topic. In particular, techniques used widely within biotechnology, especially manipulations involving recombinant DNA
techniques, have come under close regulatory scrutiny.
Although this attention has been deemed critical for ensuring both public confidence and safety, it tends to slow progress. Some federal officials now are increasingly worried that
the biotechnology regulatory net may be opening too widely.
In the rush to redirect and reclassifY agency research efforts,
making them better attuned to biotechnology's promise, the
scope of regulation may also have been inadvertently broadened too much.

Federal Panels Refining Biotechnology
Regulatory Roles
During the January 1987 meeting of the interagency Biotechnology Science Coordinating Committee (BSCC), efforts
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were made to clarifY lingering confusion about the committee's role in federal biotechnology policy-making. The upshot
of the latest discussions is that BSCC is strictly a coordinating
body-overseeing a scientific debate, albeit with many regulatory implications-but not a regulatory body. Although this
role was set at BSCC's inception, the flurry of documents,
discussions, and lawsuits surrounding proposed federal biotechnology policies in 1986 tended to obscure this circumscribed but not inconsequential charter.
Assembling information and arriving at a consensus are not
proving easy tasks for federal officials dealing with biotechnology. At best, the defining of certain key terms, such as
"pathogen" and the "deliberate release of genetically engineered organisms," is turning out to be a reiterative process.
The proposals that were published in the Federal Register
prompted an outpouring of critical and contradictory comments ( 4). Thus, not only are the proposals now not considered "enforceable" in a legal sense, they also are proving to
be just another round in a continuing cycle among scientists
from different disciplines who are seeking a purely scientific
consensus.
In addition to the BSCC's efforts to massage that collective
information, other federal agencies are going through a similar process. It could take most of 1987 before the details of
this exercise are worked out.
For example, to the Recombinant DNA Advisory Committee
(RAC) of the NIH, the issue of how to define the deliberate, or
"planned," release of genetically engineered organisms into
the environment has become a key but largely symbolic sticking point. At its February 1987 meeting, the committee urged a
further easing on current restrictions, an abstract maneuver
that can succeed only if other federal agencies evaluating
actual plans for such experiments heed NIH's intellectual
lead. Moreover, despite limiting its role reviewing most
recombinant DNA proposals that go to federal regulatory
agencies, the committee reaffirmed its intent to evaluate plans
for human gene therapy experiments, which also fall under
jurisdiction of the Food and Drug Administration (FDA).
Meanwhile at the Environmental Protection Agency (EPA),
science advisory panels consisting of outside experts have
been convened to help agency staff members develop a better
definition of deliberate release. The improved definition is
expected to serve as a guide for when projects involving a
"significant new use" of a microbe in the environment, a
release for research and development of a commercial product, or organisms falling under jurisdiction of the Toxic
Substances Control Act should undergo review by the agency.
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Fine tuning a definition to meet this goal is not proving a
straightforward chore.

Courts Playing Key Role in Shaping Regulations
The U. S. District Court late in 1986 dismissed two lawsuits
brought by activist Jeremy Rifkin protesting how the federal
government proposes to regulate biotechnology (2, 3). In
both cases, Judge Gerhard A. Gesell concluded the issues
were "not ripe" for litigation and that Rifkin and his Foundation on Economic Trends lack standing to oversee what are
properly federal policy-making prerogatives (2). The judge's
decisions could represent a serious setback to Rifkin's heretofore most effective tactic-taking legal action to slow the
progress of genetic engineering. In a separate action also
brought by Rifkin, the courts have ordered the Department of
Defense (DoD) to prepare an environmental impact statement for its entire biotechnology-based biological warfare
defense program.
In one of his lawsuits, Rifkin (3) was seeking to prevent the
President's Office of Science and Technology Policy ( OSTP)
from implementing its "Coordinated Framework for Regulation of Biotechnology," proposed in the Federal Register in
June 1986 (2 , 4, 5). In the second suit, Rifkin was objecting to
EPA's procedures for evaluating experiments involving deliberate release of genetically engineered organisms (3 ). In the
third suit, Rifkin and the other plaintiffs alleged that the DoD
was careless in conducting research on certain pathogens and
thus the whole biological warfare program needed a thorough
review for safety as well as improvements in security procedures (3).
Rifkin's action against EPA dates back to May 1986 when he
petitioned the agency to change its procedures for evaluating
and registering genetically engineered "pesticides" (3 ).Judge
Gesell cited Supreme Court decisions indicating the court
cannot settle grievances involving alleged injuries that are
merely "abstract, conjectural, or hypothetical." Thus, he
turned down Rifkin 's lawsuit, calling its grievances "wholly
abstract. " Although Judge Gesell said that the issues brought
up in Rifkin's lawsuit are not ripe for judicial review, he left
open the possibility of conducting such review later, but "in a
far more concrete factual setting" (2).
In the second lawsuit, Rifkin wanted the court to declare
OSTP's proposed Coordinated Framework for Regulation of
Biotechnology illegal. He argued that the inexactness of the
definitions that are laid out in the framework could lead to
incomplete and possibly dangerous regulation of genetically
engineered products. He also said the document needed to
be accompanied by an environmental impact statement (3).
Judge Gesell again rejected Rifkin's claims, saying in effect
that Rifkin was accusing the framework of failing at something
it is not intended to do. "While the document is not a model of
clarity... [its contents] are ... to guide policy-making, not to regulate," the judge says in his decision. Moreover, the framework is "merely a first effort to aid in formulation of agency
policy... [and] the definitions do not authorize agency action
that could not otherwise take place." Thus, the judge concludes that Rifkin's legal action was premature, based on
"abstract speculation about what the agencies involved may
do in the future" (2).
In yet another lawsuit, DoD was told in February 1987 by a
U.S. District Court judge to prepare a comprehensive environmental impact statement for its biological defense research
program, much of which involves applications ofbiotechnology warfare. Judging just who won this round ultimately
reflects on an assessment of Rifkin and the military's intenVolume 53, Number 1, 1987/ 88

tions. Rifkin asserts there are hints of sinister activities within
DoD's overall program. DoD scientists retort that their
research aims are legitimate and that valuable efforts to combat dangerous, sometimes woefully neglected diseases may
be hampered because ofRifkin's meddling. They also suggest
that Rifkin's allegations are by now a familiar means for gaining publicity. Rifkin says it is his duty to slow DoD's progress,
which he sees as leading inevitably towards weapons development, by being a "pain" (6).
The DoD programs include developing pathogen detection
systems, vaccines, and biological safety suits to protect against
potential biological warfare agents. Top Defense Department
officials have maintained that the United States follows the
Geneva Conventions forbidding development and production of biological weapons and thus all work being done is
strictly for defensive purposes. DoD's research is conducted in
many facilities across the country, with a sizable fraction of it
being done under contract in university settings. ( 6).
Although some DoD scientists question the need for a
comprehensive review because they believe their laboratory
practices are safe and environmentally sound, they view it as
potentially a "worthwhile exercise" for proving their case in
"the eyes of the public." However, they also say the suit has
been an "embarrassment" because of its "implications of
wrong doings," which they vigorously deny. According to
several observers, Rifkin 's actions ironically could lead DoD
into a more secretive posture. If DoD eventually insists on
classifying much of the material in the environmental impact
statement, notes another observer, later efforts to use that
material for delaying particular components of biological warfare programs are that much more likely to prove fruitless (6).

Public Interest Groups Revising Their
Biotechnology Agenda
Besides Rifkin, other members of the public interest community, including Barry Commoner and Ralph Nader, convened in November 1986 at a meeting, "Creating a Public
Agenda for Biotechnology: Health, Food, and the Environment," sponsored by the Boston-based Committee for
Responsible Genetics ( CRG). Also attending the meeting
were activists from West Germany, including members of the
Green Party, who provided a flavor for the militant opposition
to biotechnology that is developing in parts of Western
Europe.
Commoner and Nader, although comparative newcomers
to the biotechnology scene, seem eager to match Rifkin in
their accusations against the new industry. Indeed, they
offered strong and dire warnings of biotechnology's future
misdeeds, based mainly on their appraisals of other tech·
nology-based industries.
Other elements of the public interest community showed
themselves eager to join Rifkin, Nader, and Commoner in
their watchdog roles. Just where they want to go, or why, is not
so easy to say, however. Is biotechnology to be blocked
'altogether, or do the activists see themselves correcting the
young industry's "exploitative" tendencies and putting it onto
a track that better meets with their approval? No clear consensus has emerged.
Some efforts within biotechnology seem to have members
of the public interest community especially perplexed. For
instance, factions from among groups represented at the CRG
meeting declared themselves interested in developing particular biotechnology-based products, especially vaccines, to
benefit countries of the developing world. Vaccines are quite
appealing to many members of the public interest commun-
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ity, who recognize their value as a preventive, cost-effective
means for tackling difficult disease problems in both industrialized and developing countries. They claim, however, that
current profit-minded companies are failing to supply that
need, and will continue to fail unless invested with social
consciences.

Important Developments but also Frustrations
for Farm Sector
In response, some industrial biotechnologists are calling
upon leaders from the academic community to come forward
and "demystify" genetic engineering. "We should not let a
handful of idealogues set public policy," says Howard
Schneiderman, senior vice president for research and development at Monsanto Corp. in St. Louis. "The new technology
will hasten the change of U.S. agriculture-whether or not it is
adopted by U.S. farmers," he adds. "[They must] either
become innovative farmers or compete with one." (7).
Biotechnology's most ardent critic, Jeremy Rifkin, has
argued that some of the first agricultural products of genetic
engineering should be rejected, among other reasons, on
economic grounds. For example, administering growth hormone (also called somatotropin) to dairy cows to increase
milk production when there already is a milk glut would drive
many small dairy farmers out of business, he argues. Such
reasoning is the basis of one of his many legal actions to block
biotechnology.
Proponents of this new hormone-based technology have
developed several counterarguments. For example, according
to economist Robert Kalter of Cornell University in Ithaca,
New York, genetically engineered growth hormone could
prove relatively cheap for small dairy farmers because its use
entails no capital cost, but only the added cost of buying and
administering the hormone. Moreover, its use would reduce
feed, land, and numbers of cows needed per unit of
production-all of which may benefit small farm operations.
Because the diets of hormone-treated animals would need
substantial adjusting, the biggest changes might be expected
in land use, with demand increasing for land to grow highprotein soybeans but decreasing for land for other feed, such
as corn (7).
Still other arguments are being advanced on behalf of
growth hormone's use in agriculture. Not only does it boost
milk production and feed efficiency in dairy cattle, it also
improves productivity in hogs and cattle being raised for meat.
Perhaps more significantly, the hormone dramatically decreases the fat content of meat, and it leaves no residues,
according to Thomas Wagner of Ohio University in Athens.
Thus, it could be a safer alternative to both antibiotics used in
subtherapeutic doses and steroid hormones for boosting production in livestock, he says. Moreover, lowering fat content of
meat could prove more healthful to consumers, who have
been urged by health authorities to eat less animal fat to help
prevent heart disease and cancer.
If the foodstuffs of the genetic engineering era are being
portrayed as beneficial to consumers, other biotechnology
wares are being called "friendly to the environment."
Moreover, sometimes industrial successes may come by following "mid-level" instead of high technology, according to
David Reed of Molecular Genetics Inc. in Minnetonka, Minn.
(7). Although Reed did not say as much, another advantage of
such a strategy, besides the often faster development of useful
technologies, is a lower regulatory profile to the industry's
critics. Rifkin, for instance, seldom has strayed from matters
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that directly involve recombinant DNA techniques. Other
novel biotechnologies usually are spared his obstructionism.

Confidence in Other Industry Sectors Growing
Although experts are frustrated by current regulatory uncertainties now retarding biotechnology's application, particularly in the agriculture and food industries, they also evince
confidence in their own growing scientific and technical
know-how. They claim that biotechnology not only will
benefit farmers and food processors but also consumers,
whose food will become cheaper and more nutritious. And
growth in the pharmaceutical industry already is having an
impressive impact.
The biotechnology industry has reached "young adulthood," according to financial analyst Linda I. Miller, who
follows its commercial developments for Paine Webber Inc. in
New York City. According to her financial overview of the
industry, it is youthful but apparently thriving ( 8 ). Moreover,
the pharmaceutical industry, in offering an overview of its
1986 performance, is emphasizing how much money is being
poured into research by the industry. Representatives from the
industry point with pride to four biotechnology-based pharmaceutical products approved by the Food and Drug Administration (FDA) last year and say they expect this segment of the
industry also to continue growing. Incremental changes for
biotechnology research support also are embedded in the
Administration's budget for fiscal year (FY) 1988. (Also, see
Table 1, which indicates comprehensive federal budget figures for FY 1985.)
Table 1. GAO report summarizes biotechnology research support
among selected federal agencies in Fy 85*
Agency

USDA
ARS
CSRS
EPA
FDA
NIH
NSF

Total R&D

Biotechnology R&D

$ millions/number

$ millions/number

projects

projec s

470/2300
284/12,250
320/NA
82/NA
4,824/30,000
1,346/14,157

25/NA
48/750
1/19
3/17
1849/NA
82/1,621 to 1,773

*Source: "Biotechnology: Analysis of Federally Funded Research," U.S.
General Accounting Office Report RCED-86-187.
Abbreviations: R&D= research and development; FY =fiscal year; USDA
= U_S. Department of Agriculture; ARS =Agricultural Research Service;
CSRS = Cooperative State Research Service; EPA = Environmental
Protection Agency; FDA = Food and Drug Administration; NIH =
National Institutes of Health; NSF= National Science Foundation; NA =
not available

The biotechnology industry has grown to an impressive
size in the past few years, according to Miller. Wall Street now
accords the 50 or 60 publicly held companies an overall value
of $9 to $10 billion, based on the selling price of the available
aggregate stocks. Last year was a healthy year in terms of how
much new money was put into the industry by investors, she
notes. Marketplace funding accounted for about $800 million
worth of investment in 1986, and private placements pushed
last year's total private sector investment over $1 billion (8).
All this money is pouring into companies whose promises
for products and profits are largely still to be realized. Nonetheless, more and more products are making their way into
the marketplace, with estimates for total sales in 1986 of
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almost $500 million, which could double this year, Miller says.
The industry still is reporting overall losses but may break
even in 1987, particularly if several promising drugs are
approved for use in humans (8).
Most of the biotechnology-based products now being sold
are medical diagnostic devices, with only a handful of human
therapeutic products yet approved. Thus, although about twothirds of the private-sector biotechnology investment supports research and development of products for human therapy, they still represent a much smaller fraction of sales-reflecting the relatively more complicated approval process for
them. Diagnostic products, by contrast, receive only about
10% of the overall investment but currently account for about
55% of all sales.
So far, at least, the development costs for biotechnologybased products have been lower than those typical for new
chemical drugs, Miller continues. The new industry has had
relative good fortune with regulators, she says, particularly in
receiving expeditious review by the FDA. Patent fights, state
and local regulations, the effect of federal efforts to reduce
hospital costs (hence, possibly also to lower the costs of drugs
and diagnostic products), and the return of inflation are
among the issues that could prove to cause difficulties in the
future (8).
From the group of pharmaceuticals approved in 1986, four
products were derived from biotechnology: a monoclonal
antibody for preventing immune rejection of kidney transplants ( Orthoclone, developed by Ortho Pharmaceutical
Corp.), two versions of alpha interferon for treating hairy cell
leukemia (Intron A. developed by Schering-Plough Corp.)
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and Roferon A, developed by Hoffmann-La Roche Inc., and a
recombinant DNA-based vaccine for preventing hepatitis B
(Recombivax HB, developed by Merck Sharp & Dohme).
According to Pharmaceutical Manufacturers Association
(PMA) president Gerald Mossinghoff and his colleague William Szkrybalo, 1, 232 U.S. biotechnology patents were issued
in 1986, an increase of 14% over 1985. Although about half
those patents were for pharmaceutical and healthcare products, nearly two-thirds of the patents in this subgroup were
awarded to individuals not at U.S. firms (9).

References
1.

2.
3.
4.

5.
6.
7.
8.
9.

ASM News 52(11): 566-567. 1986.
Fox,].L. 1987. BSCC refines and limits its regulatory role.
BioTech. 5:202-203.
Fox, ].L. 1987. Public opinion: sense vs. sensibility. BioTech. 5:14.
Office of Science and Technology Policy. June 26, 1986.
Coordinated framework for regulation of biotechnology:
announcement of policy and notice for public comment.
Federal Register 51 :23, 302-23, 350.
Fox, ].L. 1986. Court orders DoD to assess impact of
biological defense. BioTech. 5:328.
Fox, ].L. 1987. Eyeing biotech's agricultural applications.
BioTech. 5:119.
Fox, ].L. 1987. Eyeing biotech's agricultural applications.
BioTech. 5:119.
Fox,].L. 1987. Industry outlook: black ink? BioTech. 5:330.
Fox, ].L. 1987. PMA statistics: 1986 themes: product and
patent approvals. BioTech. 5:204.

7

